The nonsteroidal anti‐inflammatory drug (NSAID) sulindac sulfide inhibits colon cancer cell growth by suppressing Wnt/β‐catenin signaling via the cGMP/protein kinase G (PKG) pathway 26. The gene discussed is PRKG1; the disease is malignant colon neoplasm.